Panacea Biotec Ltd: Stock Analysis & Fundamentals

Updated this week

Panacea Biotec Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. ROE: -4.9%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

🌐FII stake increased 0.7% this quarter

Key Numbers

Current Price

₹320

Market Cap

2.0K Cr

Valuation

N/A

← Back to Pharma - Others Dashboard

Frequently Asked Questions: Panacea Biotec Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Panacea Biotec Ltd's latest quarterly results?

Panacea Biotec Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -12.4%
Revenue Growth YoY: +1.0%
Operating Margin: 7.1%

What is Panacea Biotec Ltd's price-to-book ratio?

Panacea Biotec Ltd's price-to-book ratio is 2.4x.

Price-to-Book (P/B): 2.4x
Book Value per Share: ₹135
Current Price: ₹320

Is Panacea Biotec Ltd a fundamentally strong company?

Panacea Biotec Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): -5.0%

Is Panacea Biotec Ltd debt free?

Panacea Biotec Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹23 Cr

What is Panacea Biotec Ltd's return on equity (ROE) and ROCE?

Panacea Biotec Ltd's return ratios over recent years

FY2023: ROCE -10.0%
FY2024: ROCE -3.0%
FY2025: ROCE -5.0%

Is Panacea Biotec Ltd's cash flow positive?

Panacea Biotec Ltd's operating cash flow is negative (FY2025).

Cash from Operations (CFO): ₹-27 Cr
Free Cash Flow (FCF): ₹38 Cr

What is Panacea Biotec Ltd's dividend yield?

Panacea Biotec Ltd currently does not pay a significant dividend (yield 0.00%).

Dividend Yield: 0.00%
Current Price: ₹320

Who holds Panacea Biotec Ltd shares — promoters, FII, DII?

Panacea Biotec Ltd's shareholding pattern (Dec 2025)

Promoters: 72.5%
FII (Foreign): 1.4%
DII (Domestic): 1.9%
Public: 24.3%

Is promoter holding increasing or decreasing in Panacea Biotec Ltd?

Panacea Biotec Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 72.5% (Dec 2025)
Previous Quarter: 72.5% (Sep 2025)
Change: 0.00% (stable)

Is Panacea Biotec Ltd a new momentum entry or an established outperformer?

Panacea Biotec Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Panacea Biotec Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Panacea Biotec Ltd may be worth studying

Currently showing mixed signals — monitor for clearer trend confirmation

What is the investment thesis for Panacea Biotec Ltd?

Panacea Biotec Ltd investment thesis summary:

What is the future outlook for Panacea Biotec Ltd?

Panacea Biotec Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.